Peng Shi, Xu Long-Wei, Che Xin-Yu, Xiao Qing-Qing, Pu Jun, Shao Qin, He Ben
Department of Cardiology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Front Pharmacol. 2018 May 3;9:438. doi: 10.3389/fphar.2018.00438. eCollection 2018.
Atherosclerosis is a chronic disease comprising intima malfunction and arterial inflammation. Recent studies have demonstrated that autophagy could inhibit inflammatory response in atherosclerosis and exert subsequent atheroprotective effects. Our previous study also demonstrated the role of autophagy in the inhibition of inflammation by atorvastatin . Therefore, in the present study, we aimed to determine whether atorvastatin could upregulate autophagy to inhibit inflammatory cytokines secretion, lipid accumulation, and improve vulnerable plaque stability, both and . First, we established a vulnerable atherosclerotic plaque mouse model through partial ligation of left common carotid artery and left renal artery to explore the effect of atorvastatin on vulnerable plaques. The results showed that atorvastatin could enhance the stability of vulnerable atherosclerotic plaques and reduce the lesion area in the aorta. Atorvastatin could also inhibit NLRP3 inflammasome activation and inflammatory cytokines, such as IL-1β, TNF-α, and IL-18 secretion . Atorvastatin treatment upregulated the expression of autophagy-related protein microtubule-associated protein light chain (LC3B) and downregulated the expression of SQSTM1/p62, which suggested that autophagy was activated in vulnerable plaques. Transmission electron microscopy further demonstrated the atorvastatin-induced increase in autophagy activity in vulnerable atherosclerotic plaques. We employed oxidized low-density lipoprotein (ox-LDL) to stimulate RAW264.7 cells with atorvastatin, which showed that atorvastatin could attenuate lipid deposition, ameliorate inflammation, inhibit NLRP3 inflammasome activation, and enhance autophagy . All these beneficial effects were abolished by 3-methyladenine treatment, an autophagy inhibitor. Atorvastatin also significantly inhibited the phosphorylation of mTOR, which strongly suggested the involvement of the mTOR pathway. Our study proposed a new role for atorvastatin as an autophagy inducer to exert anti-inflammatory and atheroprotective effects, to stabilize vulnerable atherosclerotic plaques.
动脉粥样硬化是一种包括内膜功能障碍和动脉炎症的慢性疾病。最近的研究表明,自噬可以抑制动脉粥样硬化中的炎症反应,并发挥随后的抗动脉粥样硬化作用。我们之前的研究也证明了自噬在阿托伐他汀抑制炎症中的作用。因此,在本研究中,我们旨在确定阿托伐他汀是否可以上调自噬以抑制炎性细胞因子分泌、脂质积累,并改善易损斑块稳定性,体内和体外实验均进行了研究。首先,我们通过部分结扎左颈总动脉和左肾动脉建立了易损动脉粥样硬化斑块小鼠模型,以探讨阿托伐他汀对易损斑块的影响。结果表明,阿托伐他汀可以增强易损动脉粥样硬化斑块的稳定性,并减少主动脉中的病变面积。阿托伐他汀还可以抑制NLRP3炎性小体激活以及炎性细胞因子,如IL-1β、TNF-α和IL-18的分泌。阿托伐他汀治疗上调了自噬相关蛋白微管相关蛋白轻链(LC3B)的表达,并下调了SQSTM1/p62的表达,这表明在易损斑块中自噬被激活。透射电子显微镜进一步证明了阿托伐他汀诱导易损动脉粥样硬化斑块中自噬活性增加。我们用阿托伐他汀处理氧化型低密度脂蛋白(ox-LDL)刺激的RAW264.7细胞,结果表明阿托伐他汀可以减轻脂质沉积、改善炎症、抑制NLRP3炎性小体激活并增强自噬。所有这些有益作用都被自噬抑制剂3-甲基腺嘌呤处理所消除。阿托伐他汀还显著抑制了mTOR的磷酸化,这强烈表明mTOR通路参与其中。我们的研究提出了阿托伐他汀作为自噬诱导剂发挥抗炎和抗动脉粥样硬化作用、稳定易损动脉粥样硬化斑块的新作用。